Orchid Pharma

Orchid Pharma reported Q1 FY26 sales of INR 173 crores, marking a significant 29% year-over-year decline from INR 244 crores in the same period last year. This performance is attributed to an unprecedented^🌐 global slowdown^🌐 in the antibiotics market, characterized by both price and volume pressures. Despite these challenges, the company managed to maintain gross margins at approximately 42% through disciplined pricing and an optimized product mix. Operational EBITDA for the quarter stood at INR 14 crores, reflecting the difficult market environment.

A transformative development for Orchid Pharma is the acquisition of global rights to Enmetazobactam and the trademark Exblifep from Allecra. This acquisition grants Orchid complete control over the regulatory and commercial strategy for this novel antibiotic worldwide. Management highlighted that this makes Orchid the only Indian pharmaceutical company to innovate an internationally approved new chemical entity. While commercial terms remain confidential, the transaction is economically significant, with future double-digit royalties (estimated around 15%) from Advanz in Europe now accruing directly to Orchid.

Orchid Pharma plans to license out Enmetazobactam (Exblifep globally, Orblicef in India) to partners across the world, similar to Allecra's previous model. The product is already licensed in Europe, Middle East, and North African markets, with discussions ongoing for other geographies. The U.S. market remains a key focus, with a target to find an out-licensing partner within one year of acquisition completion. Patent expiry for Enmetazobactam is generally around early 2034 in the U.S. and similar in Europe, with ongoing pediatric studies potentially extending exclusivity.

Orblicef, Orchid's domestic brand in India, continues to perform steadily, leveraging Cipla's hospital coverage and Orchid's AMS division for prescriber awareness. The AMS division is expanding engagement with hospitals to promote responsible antibiotic use and AMR awareness, positioning Orchid as a trusted partner in critical care antibiotics. This platform is expected to drive the adoption of Cefiderocol in India, given its specialized prescriber base. The company aims to position Orblicef as a first-line antibiotic, targeting resistance to piperacillin-tazobactam and ceftriaxone.

The 7ACA project in Jammu is progressing as per revised timelines, with construction continuing and procurement of major engineering equipment completed. This facility is expected to strengthen API capabilities, reduce import dependencies, and deliver cost synergies. The commissioning of the 7ACA project is targeted for Q1 FY27. Additionally, the Cefiderocol project is on track, with commissioning expected by December '26.

The merger of Dhanuka Labs with Orchid Pharma is proceeding, with the results of the EGM accepted by the judge and final formalities expected to conclude within the next 6 months. Dhanuka Labs reported FY25 sales of INR 503 crores and an EBITDA of INR 42 crores. Management noted that the overall quantity of oral antibiotics exports from India fell by about 30% in Q1 FY26, with average export prices dropping by 15-20%. They are optimistic that the market will recover in 1-2 quarters, similar to post-COVID trends.